In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Bas D Koster,Tamarah D De Jong,Mari F C M Van Den Hout,Berbel J R Sluijter,Ronald J C L M Vuylsteke,Barbara G Molenkamp,Saskia Vosslamber,M Petrousjka Van Den Tol,Alfons J M Van Den Eertwegh,Tanja D De Gruijl

doi:10.1080/2162402x.2019.1708066

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Bas D Koster, Tamarah D De Jong + Show 8 more

Open Access

https://doi.org/10.1080/2162402x.2019.1708066

Copy DOI

Journal: OncoImmunology	Publication Date: Dec 26, 2019
Citations: 5	License type: open-access

Affiliation: Amsterdam University Medical Centers, Vrije Universiteit Amsterdam

#Early-stage Melanoma #Local Treatment Of Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ABSTRACT Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: OncoImmunology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.